Unlock stock picks and a broker-level newsfeed that powers Wall Street.

Cboe UK SEK

Xvivo Perfusion AB (publ) (XVIVOS.XC)

266.50
0.00
(0.00%)
At close: April 11 at 3:29:27 PM GMT+1
Loading Chart for XVIVOS.XC
  • Previous Close 266.50
  • Open 273.40
  • Bid 300.50 x --
  • Ask 306.00 x --
  • Day's Range 266.50 - 266.50
  • 52 Week Range 263.80 - 503.50
  • Volume 1,014
  • Avg. Volume 22
  • Market Cap (intraday) 8.801B
  • Beta (5Y Monthly) 2.08
  • PE Ratio (TTM) 48.99
  • EPS (TTM) 5.44
  • Earnings Date Apr 24, 2025
  • Forward Dividend & Yield --
  • Ex-Dividend Date --
  • 1y Target Est --

Xvivo Perfusion AB (publ), a medical technology company, develops and markets machines and perfusion solutions for assessing usable organs and maintains in optimal condition pending transplantation in Sweden. It operates through Thoracic; Abdominal; Services; and other segments. The company offers Kidney Assist Transport, a portable device that allows hypothermic pulsatile perfusion of donor kidneys with oxygenated solution for up to 24 hours; Liver Assist that provides clinicians a choice of perfusion protocols whether hypothermic, normothermic, sub-normothermic, or a combination; XVIVO System (XPS), a comprehensive ex vivo lung perfusion (EVLP) platform that offers an overview of the entire process; and STEEN Solution, a buffered extracellular solution intended for the assessment of isolated lungs after removal from the donor in preparation for eventual transplantation into a recipient. It also provides Perfadex Plus, an extracellular, low potassium, dextran-based electrolyte preservation solution; XPS Disposable Lung Kit that contains all the necessary devices and tubing to run a normothermic EVLP procedure on the XPS; XVIVO Organ Chamber, a sterile single-use container intended to be used as a temporary receptacle for isolated donor lungs; and XVIVO Lung Cannula Set, a sterile single-use set that connects isolated donor lungs to an extracorporeal perfusion system for ex-vivo assessment. In addition, the company offers Kidney Assist that provides clinicians with a choice of perfusion protocols from hypothermic to normothermic perfusion; and Gisto, an integrated system for organ transportation. It operates in Sweden; The Netherlands; The United States; Italy; North and South America; Asia/Pacific and Oceania; and internationally. The company was incorporated in 1998 and is headquartered in Mölndal, Sweden.

www.xvivogroup.com

190

Full Time Employees

December 31

Fiscal Year Ends

Recent News: XVIVOS.XC

View More

Performance Overview: XVIVOS.XC

Trailing total returns as of 4/22/2025, which may include dividends or other distributions. Benchmark is OMX Stockholm 30 Index (^OMX) .

YTD Return

XVIVOS.XC
40.61%
OMX Stockholm 30 Index (^OMX)
4.79%

1-Year Return

XVIVOS.XC
16.91%
OMX Stockholm 30 Index (^OMX)
5.86%

3-Year Return

XVIVOS.XC
11.27%
OMX Stockholm 30 Index (^OMX)
12.85%

5-Year Return

XVIVOS.XC
97.70%
OMX Stockholm 30 Index (^OMX)
54.76%

Compare To: XVIVOS.XC

Select to analyze similar companies using key performance metrics; select up to 4 stocks.

Statistics: XVIVOS.XC

View More

Valuation Measures

Annual
As of 4/17/2025
  • Market Cap

    8.80B

  • Enterprise Value

    8.42B

  • Trailing P/E

    48.99

  • Forward P/E

    49.02

  • PEG Ratio (5yr expected)

    --

  • Price/Sales (ttm)

    10.26

  • Price/Book (mrq)

    3.89

  • Enterprise Value/Revenue

    10.24

  • Enterprise Value/EBITDA

    29.14

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    20.94%

  • Return on Assets (ttm)

    2.43%

  • Return on Equity (ttm)

    8.40%

  • Revenue (ttm)

    822.41M

  • Net Income Avi to Common (ttm)

    172.18M

  • Diluted EPS (ttm)

    5.44

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    415.52M

  • Total Debt/Equity (mrq)

    1.58%

  • Levered Free Cash Flow (ttm)

    -138.93M

Research Analysis: XVIVOS.XC

View More

Company Insights: XVIVOS.XC

Research Reports: XVIVOS.XC

View More